Drug intelligence / Profile preview

ethinyl estradiol + norethindrone acetate + ferrous fumarate

Development stage
Approved
Lead developer
Allergan
Modality
Drug Delivery Systems
Administration
Oral
01

Overview

This medication is a combination hormonal contraceptive (CHC) containing norethindrone acetate (a progestin) and ethinyl estradiol (an estrogen), along with ferrous fumarate (an iron supplement)[2][3]. It works primarily by preventing ovulation - stopping a woman's egg from fully developing each month so it can no longer accept sperm, thus preventing fertilization and pregnancy[2]. The ferrous fumarate tablets are included to provide iron supplementation during the hormone-free interval of the regimen[2][7]. The medication is typically taken in a specific sequence: active hormone tablets (containing norethindrone acetate and ethinyl estradiol) for 21-24 days, followed by ferrous fumarate tablets for the remaining days of a 28-day cycle[2][6][7]. This regimen helps maintain a regular menstrual cycle while providing continuous contraceptive protection. Besides preventing pregnancy, this medication may also be prescribed to treat acne[1][5].

Brand names
Lo Loestrin FeLo Minastrin FeLoestrin FeFemcon FeJunel FeMicrogestin FeTilia FeTri-Legest FeZeosa FeCharlotte 24 FeCharlotte24 FeCharlotte-24 FeFinzalaMelodettaMibelas 24 FeMibelas24 FeMibelas-24 Fe
Other names
norethindrone-ethinyl estradiol-iron
02

Targets

PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on ethinyl estradiol + norethindrone acetate + ferrous fumarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethinyl estradiol + norethindrone acetate + ferrous fumarate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call